Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
19.04
+0.03 (0.16%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Relay Therapeutics Employees
Relay Therapeutics had 202 employees as of June 30, 2026. The number of employees increased by 5 or 2.54% compared to the same quarter last year.
Employees
202
Change
5
Growth
2.54%
Revenue / Employee
$51,238
Profits / Employee
-$1,416,025
Market Cap
4.17B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 202 | 5 | 2.54% |
| Mar 31, 2026 | 193 | -66 | -25.48% |
| Dec 31, 2025 | 192 | -69 | -26.44% |
| Sep 30, 2025 | 188 | -106 | -36.05% |
| Jun 30, 2025 | 197 | -107 | -35.20% |
| Mar 31, 2025 | 259 | -50 | -16.18% |
| Dec 31, 2024 | 261 | -62 | -19.20% |
| Sep 30, 2024 | 294 | -49 | -14.29% |
| Jun 30, 2024 | 304 | -41 | -11.88% |
| Mar 31, 2024 | 309 | -19 | -5.79% |
| Dec 31, 2023 | 323 | -4 | -1.22% |
| Sep 30, 2023 | 343 | 23 | 7.19% |
| Jun 30, 2023 | 345 | 40 | 13.11% |
| Mar 31, 2023 | 328 | 52 | 18.84% |
| Dec 31, 2022 | 327 | 82 | 33.47% |
| Sep 30, 2022 | 320 | 88 | 37.93% |
| Jun 30, 2022 | 305 | 102 | 50.25% |
| Mar 31, 2022 | 276 | 113 | 69.33% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| Iovance Biotherapeutics | 975 |
| Arcus Biosciences | 601 |
| Tarsus Pharmaceuticals | 370 |
| Dyne Therapeutics | 289 |
| IDEAYA Biosciences | 145 |
| Tango Therapeutics | 137 |
RLAY News
- 6 days ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewsWire
- 18 days ago - Relay Therapeutics price target raised to $29 from $28 at H.C. Wainwright - TheFly
- 22 days ago - Relay Therapeutics price target raised to $31 from $28 at JPMorgan - TheFly
- 4 weeks ago - Relay Therapeutics price target raised to $25 from $21 at BofA - TheFly
- 4 weeks ago - Relay Therapeutics price target raised to $26 from $21 at Citizens - TheFly
- 4 weeks ago - Relay Therapeutics price target raised to $30 from $27 at Barclays - TheFly
- 4 weeks ago - Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates - GlobeNewsWire
- 4 weeks ago - Relay Therapeutics Earnings release: Q2 2026 - Filings